BRPI0815370A2 - Anticorpos humanos de alta afinidade contra o fator de crescimento neural humano - Google Patents

Anticorpos humanos de alta afinidade contra o fator de crescimento neural humano

Info

Publication number
BRPI0815370A2
BRPI0815370A2 BRPI0815370-1A2A BRPI0815370A BRPI0815370A2 BR PI0815370 A2 BRPI0815370 A2 BR PI0815370A2 BR PI0815370 A BRPI0815370 A BR PI0815370A BR PI0815370 A2 BRPI0815370 A2 BR PI0815370A2
Authority
BR
Brazil
Prior art keywords
human
growth factor
antibodies against
neural growth
human antibodies
Prior art date
Application number
BRPI0815370-1A2A
Other languages
English (en)
Inventor
Joel C Reinhardt
Lynn Macdonald
Richard Torres
Marc R Morra
Joel H Martin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BRPI0815370A2 publication Critical patent/BRPI0815370A2/pt
Publication of BRPI0815370B1 publication Critical patent/BRPI0815370B1/pt
Publication of BRPI0815370B8 publication Critical patent/BRPI0815370B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0815370A 2007-08-10 2008-08-08 anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica BRPI0815370B8 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US96422407P 2007-08-10 2007-08-10
US60/964,224 2007-08-10
US99452607P 2007-09-20 2007-09-20
US60/994,526 2007-09-20
US6286008P 2008-01-28 2008-01-28
US61/062,860 2008-01-28
US7925908P 2008-07-09 2008-07-09
US61/079,259 2008-07-09
PCT/US2008/072561 WO2009023540A1 (en) 2007-08-10 2008-08-08 High affinity human antibodies to human nerve growth factor

Publications (3)

Publication Number Publication Date
BRPI0815370A2 true BRPI0815370A2 (pt) 2015-02-10
BRPI0815370B1 BRPI0815370B1 (pt) 2020-10-20
BRPI0815370B8 BRPI0815370B8 (pt) 2021-05-25

Family

ID=39951432

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815370A BRPI0815370B8 (pt) 2007-08-10 2008-08-08 anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica

Country Status (31)

Country Link
US (3) US7988967B2 (pt)
EP (2) EP2187964B1 (pt)
JP (1) JP5632744B2 (pt)
KR (2) KR101709488B1 (pt)
CN (1) CN101827609B (pt)
AU (1) AU2008287037B2 (pt)
BR (1) BRPI0815370B8 (pt)
CA (1) CA2695997C (pt)
CO (1) CO6261383A2 (pt)
CR (1) CR11298A (pt)
CY (1) CY1116072T1 (pt)
DK (1) DK2187964T3 (pt)
DO (1) DOP2010000054A (pt)
EC (1) ECSP10010029A (pt)
ES (1) ES2517872T3 (pt)
HR (1) HRP20141025T1 (pt)
IL (1) IL203558A (pt)
MA (1) MA31695B1 (pt)
ME (2) ME00977B (pt)
MX (1) MX2010001395A (pt)
MY (2) MY161564A (pt)
NI (1) NI201000021A (pt)
NZ (1) NZ583200A (pt)
PL (1) PL2187964T3 (pt)
PT (1) PT2187964E (pt)
RS (1) RS53661B1 (pt)
RU (1) RU2473564C2 (pt)
SI (1) SI2187964T1 (pt)
TN (1) TN2010000059A1 (pt)
WO (1) WO2009023540A1 (pt)
ZA (1) ZA201000725B (pt)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US9498530B2 (en) * 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
PL2187964T3 (pl) 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
SI2331090T1 (en) 2008-09-19 2018-04-30 Pfizer Inc. Stable liquid antibody formulation
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
AU2016202118B2 (en) * 2009-03-20 2017-10-26 Amgen Inc. Carrier immunoglobulins and uses thereof
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
MY173390A (en) * 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
KR20130031247A (ko) * 2010-03-17 2013-03-28 애보트 리서치 비.브이. 항―신경 성장 인자（ｎｇｆ） 항체 조성물
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AU2015258217A1 (en) * 2010-08-19 2015-12-03 Zoetis Belgium S.A. Anti-NGF antibodies and their use
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9783601B2 (en) * 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
CN102198272B (zh) * 2011-05-27 2013-01-02 北京中科拜克生物技术有限公司 一种促进骨折愈合的药物组合物
RS56876B1 (sr) * 2011-08-11 2018-04-30 Astellas Pharma Inc Novo antitelo protiv humanog ngf
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
HRP20191690T1 (hr) 2012-04-27 2019-12-27 Millennium Pharmaceuticals, Inc. Molekule anti-gcc antitijela i njihova uporaba u ispitivanju osjetljivosti na gcc-ciljanu terapiju
JO3820B1 (ar) * 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
RU2666990C2 (ru) 2012-08-13 2018-09-13 Дженентек, Инк. Антитела к jagged и способы их применения
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3036543B1 (en) 2013-08-23 2019-06-19 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
AU2015209140B2 (en) * 2014-01-24 2020-01-02 William R. Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
IL282614B2 (en) 2015-02-06 2024-02-01 Cell Idx Inc Antigen-conjugated immune reagents
CN104774265B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株
CN104777311B (zh) * 2015-02-12 2016-08-17 北京华安科创生物技术有限公司 抗人神经生长因子hNGF的单克隆抗体及hNGF的定量检测试剂盒
CN104910274B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
WO2016190263A1 (ja) 2015-05-22 2016-12-01 アステラス製薬株式会社 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント
CA2994638A1 (en) * 2015-08-13 2017-02-16 Merck Patent Gmbh Combination composition comprising fgf-18 compound
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
UA125025C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. Способи лікування дитячих ракових захворювань
UA125026C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
CN107286233B (zh) * 2016-04-13 2020-11-06 舒泰神（北京）生物制药股份有限公司 低痛神经生长因子突变体
MX392604B (es) 2016-05-18 2025-03-24 Array Biopharma Inc Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo.
US12123874B2 (en) * 2016-07-18 2024-10-22 Cell Idx, Inc. Reagent compounds, compositions, kits, and methods for amplified assays
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
MA45890B2 (fr) * 2016-11-29 2022-10-31 Regeneron Pharma Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
PL3558347T3 (pl) 2016-12-22 2026-04-20 Regeneron Pharmaceuticals, Inc. Sposób leczenia alergii swoistymi dla alergenu przeciwciałami monoklonalnymi
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
CN109929035B (zh) * 2017-12-15 2022-06-28 安源医药科技（上海）有限公司 抗人ngf抗体及其制备方法和用途
CN108059676B (zh) * 2017-12-28 2020-07-31 未名生物医药有限公司 一种抗人神经生长因子scFv抗体及制备方法
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
WO2019200326A1 (en) 2018-04-13 2019-10-17 Rarecyte, Inc. Kits for labeling of biomarkers and methods of using the same
CN108623687A (zh) 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用
JPWO2019221097A1 (ja) 2018-05-15 2021-05-27 アステラス製薬株式会社 抗ヒトｎｇｆ抗体又はその抗原結合フラグメントを有効成分とする心房細動の抑制用医薬組成物
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
KR20210043624A (ko) * 2018-08-10 2021-04-21 리제너론 파아마슈티컬스, 인크. 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
JP2020117502A (ja) 2019-01-28 2020-08-06 ファイザー・インク 変形性関節症の徴候および症状を処置する方法
EP3927430A1 (en) 2019-02-18 2021-12-29 Pfizer Inc. Method of treatment of chronic low back pain
CA3135181A1 (en) * 2019-04-05 2020-10-08 B-Portal Biologics, Inc. Fusion constructs and uses thereof
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
CN113924315B (zh) * 2019-06-10 2022-06-28 山东博安生物技术股份有限公司 抗β-NGF纳米抗体及其应用
EP4084818A2 (fr) * 2019-12-31 2022-11-09 Peptinov Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires
CN117050175B (zh) * 2020-04-17 2024-07-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN117186219B (zh) * 2020-04-17 2024-07-12 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
WO2021238886A1 (en) * 2020-05-27 2021-12-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Dartsbio Pharmaceuticals Ltd. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
CN116003590A (zh) 2020-08-06 2023-04-25 熙源安健医药（上海）有限公司 抗ngf抗体及其抗原结合片段、其制备方法和应用
IL301548A (en) 2020-09-28 2023-05-01 Medimmune Ltd Compounds and methods for treating pain
CN114470189B (zh) * 2020-11-12 2024-01-16 达石药业(广东)有限公司 Ngf抗体在cipn性疼痛中的应用
WO2022133094A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Fap binding molecules and uses thereof
WO2022195504A1 (en) 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
CN115725684A (zh) * 2021-08-28 2023-03-03 达石药业(广东)有限公司 一种Anti-NGF药物细胞增殖抑制活性检定方法
WO2023092052A1 (en) 2021-11-19 2023-05-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
MX2024007088A (es) 2021-12-16 2024-08-22 Intervet Int Bv Anticuerpos caninizados contra el ngf humano.
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用
US20240002491A1 (en) 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US514294A (en) * 1894-02-06 Governor
US5147294A (en) 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
RU94016525A (ru) * 1991-07-10 1996-06-10 Ридженерон Фармасьютикалз Способы лечения заболеваний двигательных нейронов
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AUPR256601A0 (en) * 2001-01-17 2001-02-08 Silverbrook Research Pty. Ltd. An apparatus (AP29)
KR20100132559A (ko) 2001-05-30 2010-12-17 제넨테크, 인크. 다양한 질환의 치료에 유용한 항-엔지에프 항체
EP1542724A4 (en) * 2002-08-19 2005-10-19 Abgenix Inc ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF
WO2004032870A2 (en) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK1575517T3 (da) * 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
UA97086C2 (uk) 2003-07-15 2012-01-10 Емджен, Інк. Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf)
EP1706425A2 (en) * 2003-12-05 2006-10-04 John R. Schreiber Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse®
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
KR101637908B1 (ko) 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
JP5096167B2 (ja) * 2005-01-24 2012-12-12 メドイミューン リミテッド Ｎｇｆに対する特異的結合メンバー
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
SI1937721T1 (sl) * 2005-08-25 2010-11-30 Lilly Co Eli Anti il protitelesa
US9789161B2 (en) 2006-04-28 2017-10-17 Warsaw Orthopedic, Inc. Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
PL2187964T3 (pl) 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada

Also Published As

Publication number Publication date
PT2187964E (pt) 2015-01-14
MA31695B1 (fr) 2010-09-01
DOP2010000054A (es) 2010-03-15
KR20150125735A (ko) 2015-11-09
US8148107B2 (en) 2012-04-03
HRP20141025T1 (hr) 2015-01-02
CN101827609B (zh) 2014-03-12
JP2010535509A (ja) 2010-11-25
DK2187964T3 (en) 2015-01-12
HK1144379A1 (en) 2011-02-18
AU2008287037B2 (en) 2013-10-10
EP2187964A1 (en) 2010-05-26
ME00977B (me) 2012-06-20
KR101709495B1 (ko) 2017-02-23
BRPI0815370B8 (pt) 2021-05-25
ECSP10010029A (es) 2010-04-30
EP2187964B1 (en) 2014-10-08
RU2010108525A (ru) 2011-09-20
NI201000021A (es) 2010-07-27
CY1116072T1 (el) 2017-02-08
ME02239B (me) 2015-04-30
CO6261383A2 (es) 2011-03-22
NZ583200A (en) 2012-03-30
RS53661B1 (sr) 2015-04-30
RU2473564C2 (ru) 2013-01-27
JP5632744B2 (ja) 2014-11-26
WO2009023540A1 (en) 2009-02-19
MX2010001395A (es) 2010-03-10
BRPI0815370B1 (pt) 2020-10-20
TN2010000059A1 (fr) 2011-09-26
SI2187964T1 (sl) 2015-01-30
US20120164688A1 (en) 2012-06-28
MY161564A (en) 2017-04-28
CA2695997C (en) 2016-11-22
PL2187964T3 (pl) 2015-03-31
KR20100058537A (ko) 2010-06-03
CR11298A (es) 2010-03-23
US7988967B2 (en) 2011-08-02
US8613927B2 (en) 2013-12-24
ZA201000725B (en) 2011-06-29
MY153781A (en) 2015-03-13
EP2572729A3 (en) 2013-06-05
ES2517872T3 (es) 2014-11-04
IL203558A (en) 2014-03-31
US20110256587A1 (en) 2011-10-20
US20090041717A1 (en) 2009-02-12
AU2008287037A1 (en) 2009-02-19
CA2695997A1 (en) 2009-02-19
EP2572729A2 (en) 2013-03-27
CN101827609A (zh) 2010-09-08
KR101709488B1 (ko) 2017-02-24

Similar Documents

Publication Publication Date Title
PT2376537T (pt) Anticorpos humanos contra fator tecidual humano
EP2004241A4 (en) Implantable sensor
ZA201307297B (en) Antibodies against human angiopoietin 2
IL211684A0 (en) Antibodies against human il 17 and uses thereof
DK2222706T3 (da) Antibodies against human nkg2d and uses thereof
LTPA2016001I1 (lt) Antikūnai prieš žmogaus užprogramuotą mirties receptorių pd-1
EP2207803A4 (en) CD9-SPECIFIC HUMAN ANTIBODIES
BRPI0909908A2 (pt) implante de válvula cardíaca
EP2231061A4 (en) Implantable prosthesis
PL2949666T3 (pl) Ludzkie przeciwciała przeciwko alfa-synukleinie
EP2119463A4 (en) MEDICAL CONTAINER
BRPI0910809A2 (pt) "aplicador de tampão"
DE602007004789D1 (de) Manipulator zur medizinischen Verwendung
BRPI1013015A2 (pt) "osteosíntese com nanoprata"
BRPI0912157A2 (pt) manufatura de bolsas conter espécimes biológicos
BRPI0819014A2 (pt) "descanso de braço"
FR2913196B1 (fr) Implant oculaire accomodatif
IL218890A0 (en) Human anti-b7rp1 neutralizing antibodies
EP2171592A4 (en) PARALLELIZATION OF SEQUENCIAL FRAMEWORK CONDITIONS USING TRANSACTIONS
EP2147926A4 (en) TRUNCATED L1 PROTEINS OF THE HUMAN PAPILLOMA AVIRUS TYPE 18
BRPI0916092A2 (pt) "isoformas específicas de anticorpos anti-her4"
EP2239323A4 (en) HUMANIZED ANTIHUMAN 9 INTEGRIN ANTIBODY
BRPI0923161A2 (pt) "dispositivo implantável"
EP2299483A4 (en) RIGGED DOUBLE SERVO NANO BREED
EP2117591A4 (en) REDUCING TUMOR GROWTH

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF